سعر بيستول بلس Bistol Plus‏ 5/12.5 مجم 20 قرص 2026

Bistol Plus 5/12.5 Mg 20 F.C.Tab (20 film-coated tablets), antihypertensive (beta-blocker + thiazide diuretic) marketed in Egypt by Hikma Pharma.

• Hypersensitivity to the actives, other thiazides or sulfonamides; acute heart failure or decompensation needing IV inotropes; cardiogenic shock; second/third-degree AV block without pacemaker; sick sinus syndrome; sinoatrial block; symptomatic bradycardia; severe asthma; severe peripheral arterial occlusive disease or Raynaud's; untreated phaeochromocytoma; severe renal impairment (CrCl ≤30 mL/min); severe hepatic impairment; metabolic acidosis; refractory hypokalaemia; severe hyponatraemia; hypercalcaemia; gout.International label, same formulation · Federal Agency for Medicines and Health Products (FAMHP / FAGG-AFMPS), Belgium

• Long-term hydrochlorothiazide may cause hypokalaemia, hyponatraemia, hypomagnesaemia, hypochloraemia and hypercalcaemia (hypokalaemia promotes torsade de pointes); monitor electrolytes, creatinine, urea, lipids, uric acid and glucose; gout risk in hyperuricaemia; choroidal effusion, acute myopia and angle-closure glaucoma; very rare acute respiratory distress syndrome; beta-blocker cautions (heart failure, diabetes, bronchospasm, no abrupt withdrawal).International label, same formulation · Federal Agency for Medicines and Health Products (FAMHP / FAGG-AFMPS), Belgium

• LithiumReduced lithium excretion with increased cardiotoxicity and neurotoxicity (not recommended).Federal Agency for Medicines and Health Products (FAMHP / FAGG-AFMPS), Belgium
• Verapamil/diltiazem-type calcium antagonistsNegative effect on contractility and AV conduction; IV verapamil may cause profound hypotension and AV block.Federal Agency for Medicines and Health Products (FAMHP / FAGG-AFMPS), Belgium
• Centrally acting antihypertensivesFurther fall in heart rate and output; rebound hypertension on abrupt withdrawal.Federal Agency for Medicines and Health Products (FAMHP / FAGG-AFMPS), Belgium

• Bisoprolol may reduce placental perfusion (growth retardation, intrauterine death, abortion, preterm labour) with possible fetal/neonatal hypoglycaemia and bradycardia; hydrochlorothiazide may cause fetoplacental ischaemia and possibly neonatal thrombocytopenia. Not recommended in pregnancy unless clearly necessary.International label, same formulation · Federal Agency for Medicines and Health Products (FAMHP / FAGG-AFMPS), Belgium
• Not recommended during breastfeeding: bisoprolol may and hydrochlorothiazide does pass into breast milk; hydrochlorothiazide may reduce milk production.International label, same formulation · Federal Agency for Medicines and Health Products (FAMHP / FAGG-AFMPS), Belgium

• Bisoprolol fumarate: Highly beta-1-selective adrenoceptor blocker without intrinsic sympathomimetic or relevant membrane-stabilising activity; reduces heart rate, contractility and sympathetic drive.
• Hydrochlorothiazide: Promotes renal excretion of sodium and chloride, reducing intravascular volume.